Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
Neurocrine Biosciences (NBIX) will present at the Canaccord Genuity 44th Annual Growth Conference in Boston on August 14, 2024, at 3:30 p.m. Eastern Time. Kyle Gano, Chief Business Development and Strategy Officer, and Todd Tushla, Vice President of Investor Relations, will represent the company. The presentation will be webcast live and accessible on Neurocrine's website, with a replay available for approximately one month.
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Their portfolio includes FDA-approved treatments for tardive dyskinesia, Huntington's disease-associated chorea, endometriosis, and uterine fibroids. The company has a robust pipeline with multiple compounds in mid to late-phase clinical development.
Neurocrine Biosciences (NBIX) presenterà alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity a Boston il 14 agosto 2024 alle 15:30 ora orientale. Kyle Gano, Direttore dello Sviluppo Commerciale e della Strategia, e Todd Tushla, Vice Presidente delle Relazioni con gli Investitori, rappresenteranno l'azienda. La presentazione sarà trasmessa in diretta e accessibile sul sito web di Neurocrine, con una registrazione disponibile per circa un mese.
Neurocrine Biosciences è un azienda biofarmaceutica focalizzata sulle neuroscienze dedicata allo sviluppo di trattamenti per disturbi neurologici, neuroendocrini e neuropsichiatrici. Il loro portafoglio include trattamenti approvati dalla FDA per la discinesia tardiva, la corea associata alla malattia di Huntington, l'endometriosi e i fibromi uterini. L'azienda ha un pipeline robusto con più composti in fase clinica intermedia e avanzata.
Neurocrine Biosciences (NBIX) presentará en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity en Boston el 14 de agosto de 2024 a las 3:30 p.m. Hora del Este. Kyle Gano, Director de Desarrollo Comercial y Estrategia, y Todd Tushla, Vicepresidente de Relaciones con Inversores, representarán a la empresa. La presentación se transmitirá en vivo y será accesible en el sitio web de Neurocrine, con una repetición disponible durante aproximadamente un mes.
Neurocrine Biosciences es una empresa biofarmacéutica centrada en la neurociencia dedicada al desarrollo de tratamientos para trastornos neurológicos, neuroendocrinos y neuropsiquiátricos. Su cartera incluye tratamientos aprobados por la FDA para la discinesia tardiva, la corea asociada a la enfermedad de Huntington, la endometriosis y los fibromas uterinos. La empresa tiene un sólido pipeline con múltiples compuestos en desarrollo clínico de fases intermedias a avanzadas.
Neurocrine Biosciences (NBIX)는 Canaccord Genuity 제44회 연례 성장 회의에서 2024년 8월 14일 오후 3시 30분 동부 표준시(EST)에 보스턴에서 발표할 예정입니다. 이 회사는 Kyle Gano(사업 개발 및 전략 최고 책임자)와 Todd Tushla(투자자 관계 부사장)가 대표합니다. 발표는 실시간 웹캐스트로 진행되며 Neurocrine 웹사이트에서 접근할 수 있으며, 약 한 달 동안 재생할 수 있습니다.
Neurocrine Biosciences는 신경과학 중심의 바이오 제약 회사로, 신경계, 신경내분비 및 신경정신과 장애에 대한 치료제를 개발하는 데 전념하고 있습니다. 이들의 포트폴리오에는 FDA 승인 치료제가 포함되어 있으며, 지연성 운동 이상증, 헌팅턴병 관련 무도증, 자궁내막증, 자궁근종에 대한 연구개발이 포함됩니다. 이 회사는 중간에서 후기 단계의 임상 개발 중인 여러 화합물이 있는 견고한 파이프라인을 보유하고 있습니다.
Neurocrine Biosciences (NBIX) présentera lors de la 44e Conférence Annuelle sur la Croissance de Canaccord Genuity à Boston le 14 août 2024 à 15h30, heure de l'Est. Kyle Gano, Directeur du Développement Commercial et de la Stratégie, et Todd Tushla, Vice-Président des Relations Investisseurs, représenteront l'entreprise. La présentation sera diffusée en direct et accessible sur le site web de Neurocrine, avec un enregistrement disponible pendant environ un mois.
Neurocrine Biosciences est une entreprise biopharmaceutique axée sur les neurosciences dédiée au développement de traitements pour des troubles neurologiques, neuroendocriniens et neuropsychiatriques. Leur portefeuille comprend des traitements approuvés par la FDA pour la dyskinésie tardive, la chorée associée à la maladie de Huntington, l'endométriose et les fibromes utérins. L'entreprise dispose d'un pipeline solide avec plusieurs composés en développement clinique de phase intermédiaire à avancée.
Neurocrine Biosciences (NBIX) wird auf der 44. Jahreskonferenz für Wachstumsinvestitionen von Canaccord Genuity in Boston am 14. August 2024 um 15:30 Uhr Eastern Time präsentieren. Kyle Gano, Chief Business Development and Strategy Officer, und Todd Tushla, Vice President of Investor Relations, werden das Unternehmen vertreten. Die Präsentation wird live übertragen und auf der Website von Neurocrine verfügbar sein, mit einer Wiederholung, die etwa einen Monat lang verfügbar ist.
Neurocrine Biosciences ist ein biopharmazeutisches Unternehmen mit Schwerpunkt auf Neurowissenschaften, das sich der Entwicklung von Behandlungen für neurologische, neuroendokrine und neuropsychiatrische Erkrankungen widmet. Ihr Portfolio umfasst von der FDA genehmigte Behandlungen für tardive Dyskinesie, chorea bei Huntington-Krankheit, Endometriose und Uterusmyome. Das Unternehmen verfügt über eine robuste Pipeline mit mehreren Verbindungen in der klinischen Entwicklung in der mittleren bis späten Phase.
- None.
- None.
The live presentation will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with
NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-302217036.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When and where will Neurocrine Biosciences (NBIX) present at the Canaccord Genuity conference?
Who will represent Neurocrine Biosciences (NBIX) at the Canaccord Genuity conference?
How can investors access Neurocrine Biosciences' (NBIX) presentation at the Canaccord Genuity conference?
What are some of the FDA-approved treatments in Neurocrine Biosciences' (NBIX) portfolio?
What is the main focus of Neurocrine Biosciences (NBIX) as a company?
